FOY has recently been administered to the DIC patients for its anti-coagulative function. In this paper, the effects of FOY on 41 patients associated with DIC, who had hematological neoplastic disorders, were studied. The severity of DIC was shown by score count according to the DIC diagnostic criteria, which was proposed by Maekawa and others, with partial modification.
FOY was administered at the dose of 1∼2mg/kg/hour by continuous intravenous drip infusion, or by intermittent drip infusion of the same daily dose for more than 4 consecutive days.
Therapeutic effects of FOY were evaluated by the change of the score counts or clinical symptoms independently.
The effective rate was 90.0% in AML, 72.7% APL, 77.8% ALL and 70.0% others (mean 75.6%).
These results indicated that FOY was effective on improving the DIG state in patients with hematological neoplastic disorders. And it was suggested that FOY therapy might be useful especially in DIC patients who were accompanied with low AT-III level or heparin-induced thrombocytopenia.
